Alkermes launches a phase 2 trial of oral orexin-2 agonist ALKS 7290 to boost antidepressant response in major depressive disorder, assessing safety and symptom relief.
Feature|Articles|February 19, 2025
What Went Wrong? Top 6 Clinical Disappointments
Author(s)Leah Kuntz
What are the top 6 disappointing psychopharmacological updates from the past year? We rank the top 6.
Advertisement
Advertisement
While science is all about trial and error, it can be easy to feel disappointed when a new potential treatment fails in the development process. Here, we highlight the most disappointing outcomes in the psychiatric treatment pipeline from the last year.
Related to this article
Cingulate shares plans to resubmit its ADHD candidate CTx-1301 to the FDA, following a CRL tied to CMC information requests
Compass Pathways has completed its submission of an NDA to the FDA for COMP360 psilocybin for treatment-resistant depression.
GLP-1 drugs enter psychiatry, curbing antipsychotic weight gain while raising new questions about addiction, mood, eating disorders, and culture.
Sabirnetug phase 2 Alzheimer trial misses cognitive endpoint despite lowering amyloid, prompting Acumen to halt development and open-label extension plans.
Neflamapimod misses its main DLB endpoint, but biomarker and subgroup signals suggest IL-1β pathway impact and may justify a phase 3 trial.
The evidence points toward an overall protective effect in adult cohorts and no increase in completed suicide in younger populations.
Explore how OCD and schizophrenia overlap, complicating diagnosis and care, and learn spectrum-based strategies and treatment pitfalls for managing schizo-obsessive symptoms.
Advertisement
Advertisement